<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:e sem="disease" ids="C0026986" disease_type="Neoplastic Process" abbrv="MDS">Preleukemic syndromes</z:e> compose a group of acquired <z:e sem="disease" ids="C0005956" disease_type="Disease or Syndrome" abbrv="">bone marrow disorders</z:e> characterized by dysplastic maturation of hematopoietic cells and peripheral blood cytopenias </plain></SENT>
<SENT sid="1" pm="."><plain>These syndromes have been generally considered untreatable </plain></SENT>
<SENT sid="2" pm="."><plain>We administered low doses of <z:chebi fb="1" ids="16040">cytosine</z:chebi> <z:chebi fb="0" ids="22601">arabinoside</z:chebi> by continuous infusion for 14 to 21 days (20 mg/m2/d) to 16 patients with <z:e sem="disease" ids="C0026986,C0033027" disease_type="Neoplastic Process" abbrv="">preleukemia</z:e> in various stages of evolution to <z:hpo ids='HP_0002488'>acute leukemia</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>Steady state plasma <z:chebi fb="1" ids="16040">cytosine</z:chebi> <z:chebi fb="0" ids="22601">arabinoside</z:chebi> levels ranged from 41.8 to 64.2 nmol/L </plain></SENT>
<SENT sid="4" pm="."><plain>Eleven patients demonstrated marked improvement in hematopoiesis and loss of transfusion requirements for periods ranging from two to 27 + months </plain></SENT>
<SENT sid="5" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> but one responding patient developed recurrent <z:hpo ids='HP_0001876'>pancytopenia</z:hpo>, but additional responses to low-dose <z:chebi fb="1" ids="16040">cytosine</z:chebi> <z:chebi fb="0" ids="22601">arabinoside</z:chebi> were achieved in five of five retreated patients </plain></SENT>
<SENT sid="6" pm="."><plain>Median overall survival time is 12 months for the 11 responding cases, and nine months for nonresponders </plain></SENT>
<SENT sid="7" pm="."><plain>The major toxicity of low-dose <z:chebi fb="1" ids="16040">cytosine</z:chebi> <z:chebi fb="0" ids="22601">arabinoside</z:chebi> is <z:e sem="disease" ids="C0854467" disease_type="Disease or Syndrome" abbrv="">myelosuppression</z:e>, and most patients required platelet transfusion support and administration of antibiotics </plain></SENT>
<SENT sid="8" pm="."><plain>Chromosome analyses demonstrated evolution to a new clone of hematopoietic cells in three patients, and persistence of the same abnormal clone in another patient </plain></SENT>
<SENT sid="9" pm="."><plain>These results suggest that low-dose <z:chebi fb="1" ids="16040">cytosine</z:chebi> <z:chebi fb="0" ids="22601">arabinoside</z:chebi> therapy may result in improved hematopoiesis by promoting maturation or by selecting new stem cell clones </plain></SENT>
<SENT sid="10" pm="."><plain>Low-dose <z:chebi fb="1" ids="16040">cytosine</z:chebi> <z:chebi fb="0" ids="22601">arabinoside</z:chebi> therapy thus deserves further evaluation both as a single agent and in combination with other agents in the treatment of <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> </plain></SENT>
</text></document>